GBT is now part of Pfizer! Click here for more information

Press Releases

Press Releases

Date Title
Sep 15, 2022
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
Sep 08, 2022
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
Aug 08, 2022
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Aug 04, 2022
GBT Announces New Employment Inducement Grants
Aug 03, 2022
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
Jul 29, 2022
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
Jul 26, 2022
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Jul 14, 2022
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
Jul 13, 2022
The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
Jul 07, 2022
GBT Announces New Employment Inducement Grants
Jun 29, 2022
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
Jun 16, 2022
NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease
Jun 13, 2022
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
Jun 10, 2022
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Jun 06, 2022
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
Jun 06, 2022
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
Jun 02, 2022
GBT Announces New Employment Inducement Grants
Jun 01, 2022
GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
May 12, 2022
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
May 05, 2022
GBT Announces Participation in Upcoming Investor Conferences
May 05, 2022
GBT Announces New Employment Inducement Grants
May 04, 2022
GBT Reports First Quarter 2022 Financial Results
Apr 28, 2022
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
Apr 27, 2022
GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
Apr 07, 2022
GBT Announces New Employment Inducement Grants
Mar 24, 2022
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
Mar 10, 2022
GBT Announces New Employment Inducement Grants
Mar 03, 2022
The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations
Feb 28, 2022
GBT Announces Participation in Upcoming Investor Conferences
Feb 23, 2022
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 16, 2022
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
Feb 16, 2022
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Feb 03, 2022
GBT Announces New Employment Inducement Grants
Jan 27, 2022
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
Jan 10, 2022
Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States